High lipoprotein(a) levels in type 1 diabetes linked to cardiovascular disease

December 18, 2019

High blood levels of the lipid lipoprotein(a) in people with type 1 diabetes add to the already elevated risk of developing cardiovascular disease, researchers from Karolinska Institutet in Sweden report in a paper published in the prestigious journal Diabetes Care. Lipoprotein(a) levels should therefore be measured in patients with type 1 diabetes and form part of the total risk assessment, say the researchers.

"There is currently no readily available treatment for high lipoprotein(a) levels, but the treatment of all other risk factors for cardiovascular disease should be optimised for patients with type 1 diabetes and high levels of lipoprotein(a)," says the study's lead author Karin Littmann, PhD student at the Department of Laboratory Medicine at Karolinska Institutet.

As a consequence of their disease, patients with type 1 diabetes run a higher risk of developing cardiovascular disease. Diabetes and high blood-sugar levels can also eventually cause the leakage of proteins into the urine, reduced kidney function, impaired circulation and retinal damage, leading to impaired vision.

Lipoprotein(a) is a type of blood fat, the levels of which are determined mostly by hereditary factors rather than diet or lifestyle, like other blood lipids. Previous research has shown that high levels of lipoprotein(a) entail a higher risk of cardiovascular diseases, such as myocardial infarction, stroke and calcified aortic valve disease. However, it is not fully known how lipoprotein(a) influences the risk of cardiovascular disease and related complications in patients with type 1 diabetes. It is also not known if there is any connection between lipoprotein(a) levels and high blood-sugar levels in this patient group.

For the present study, the researchers examined 1,860 patients with type 1 diabetes, and gathered data from medical records at Karolinska University Hospital on their lipoprotein(a) and blood-sugar levels, and on the incidence of cardiovascular disease and related complications.

Patients with type 1 diabetes and high lipoprotein(a) levels had a 50 per cent higher risk of developing some form of cardiovascular disease, a 70 per cent higher risk of coronary artery disease and a 100 per cent higher risk of calcified aortic valve disease, than patients with type 1 diabetes and low lipoprotein(a) levels. They also had a 70 per cent higher risk of protein leakage into the urine, which is a sign of reduced kidney function. Patients with high blood glucose (HbA1c) values had higher lipoprotein(a) levels than patients with low blood glucose values.

"Our conclusion is that high levels of lipoprotein(a) in patients with type 1 diabetes add to the already elevated risk of developing cardiovascular disease," says Dr Littmann. "The levels of these blood lipids should therefore be measured and should form part of the total risk assessment."
The study was financed by the Swedish Heart-Lung Foundation, the Swedish Research Council and Karolinska Institutet, and by an investigator-initiated study grant from the pharmaceutical company Sanofi. Sanofi did not participate in the study design, data collection and analysis, the writing of the manuscript or the decision to submit the manuscript for publication.

Publication: "The association of lipoprotein(a) plasma levels with prevalence of cardiovascular disease and metabolic control status in patients with type 1 diabetes mellitus". Karin Littmann, Tigist Wodaje, Michael Alvarsson, Matteo Bottai, Mats Eriksson, Paolo Parini, Jonas Brinck. Diabetes Care, online 18 December 2019, doi: 10.2337/DC19-1398.

Karolinska Institutet

Related Diabetes Articles from Brightsurf:

New diabetes medication reduced heart event risk in those with diabetes and kidney disease
Sotagliflozin - a type of medication known as an SGLT2 inhibitor primarily prescribed for Type 2 diabetes - reduces the risk of adverse cardiovascular events for patients with diabetes and kidney disease.

Diabetes drug boosts survival in patients with type 2 diabetes and COVID-19 pneumonia
Sitagliptin, a drug to lower blood sugar in type 2 diabetes, also improves survival in diabetic patients hospitalized with COVID-19, suggests a multicenter observational study in Italy.

Making sense of diabetes
Throughout her 38-year nursing career, Laurel Despins has progressed from a bedside nurse to a clinical nurse specialist and has worked in medical, surgical and cardiac intensive care units.

Helping teens with type 1 diabetes improve diabetes control with MyDiaText
Adolescence is a difficult period of development, made more complex for those with Type 1 diabetes mellitus (T1DM).

Diabetes-in-a-dish model uncovers new insights into the cause of type 2 diabetes
Researchers have developed a novel 'disease-in-a-dish' model to study the basic molecular factors that lead to the development of type 2 diabetes, uncovering the potential existence of major signaling defects both inside and outside of the classical insulin signaling cascade, and providing new perspectives on the mechanisms behind insulin resistance in type 2 diabetes and possibly opportunities for the development of novel therapeutics for the disease.

Tele-diabetes to manage new-onset diabetes during COVID-19 pandemic
Two new case studies highlight the use of tele-diabetes to manage new-onset type 1 diabetes in an adult and an infant during the COVID-19 pandemic.

Genetic profile may predict type 2 diabetes risk among women with gestational diabetes
Women who go on to develop type 2 diabetes after having gestational, or pregnancy-related, diabetes are more likely to have particular genetic profiles, suggests an analysis by researchers at the National Institutes of Health and other institutions.

Maternal gestational diabetes linked to diabetes in children
Children and youth of mothers who had gestational diabetes during pregnancy are at increased risk of diabetes themselves, according to new research published in CMAJ (Canadian Medical Association Journal).

Two diabetes medications don't slow progression of type 2 diabetes in youth
In youth with impaired glucose tolerance or recent-onset type 2 diabetes, neither initial treatment with long-acting insulin followed by the drug metformin, nor metformin alone preserved the body's ability to make insulin, according to results published online June 25 in Diabetes Care.

People with diabetes visit the dentist less frequently despite link between diabetes, oral health
Adults with diabetes are less likely to visit the dentist than people with prediabetes or without diabetes, finds a new study led by researchers at NYU Rory Meyers College of Nursing and East Carolina University's Brody School of Medicine.

Read More: Diabetes News and Diabetes Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.